相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Tim Grob et al.
BLOOD (2022)
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
David Andrew Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
Asmita Mishra et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
Rob S. Sellar et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David A. Sallman et al.
BLOOD (2021)
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2021)
Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
Guillermo Garcia-Manero et al.
BLOOD (2021)
Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival
Talha Badar et al.
BLOOD (2021)
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating
Daniel A. Pollyea et al.
BLOOD (2021)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Naval Daver et al.
BLOOD (2021)
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Saeid Taghiloo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Edmond Chiche et al.
BLOOD ADVANCES (2021)
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M. Hunter et al.
BLOOD ADVANCES (2021)
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax
Kunhwa Kim et al.
CANCER (2021)
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia
Nabih Maslah et al.
HAEMATOLOGICA (2020)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
Jayakumar Vadakekolathu et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu et al.
BLOOD ADVANCES (2020)
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J. Short et al.
BLOOD ADVANCES (2020)
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase
Vikas Gupta et al.
BLOOD ADVANCES (2020)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)
R. Coleman Lindsley et al.
BLOOD (2019)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development
Sarah C. Nabinger et al.
LEUKEMIA (2019)
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Dongdong Feng et al.
BLOOD (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy
Miron Prokocimer et al.
BLOOD (2017)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Tetsuichi Yoshizato et al.
BLOOD (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
Tapan M. Kadia et al.
CANCER (2016)
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Matteo G. Della Porta et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
Yu Liu et al.
NATURE (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
Vladimir J. N. Bykov et al.
FRONTIERS IN ONCOLOGY (2016)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
Ban Xiong Tan et al.
ONCOTARGET (2014)
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Vinod Pant et al.
BLOOD (2012)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Conserved Regulation of p53 Network Dosage by MicroRNA-125b Occurs through Evolving miRNA-Target Gene Pairs
Minh T. N. Le et al.
PLOS GENETICS (2011)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
C. Haferlach et al.
LEUKEMIA (2008)
MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function
KB Kindle et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes
A Willis et al.
ONCOGENE (2004)
分享论文
